pipeline AB
Cours temps réel: 1,978 0,41%| Cours | Graphes | News | Analyses et conseils | Société | Historiques | Vie du titre | Secteur | Forum |
du coup je vais me lacher ce soir sur le KC pancreas et la masto ^^
Ahh ! que c'est bon d'etre libre ^^
lol
Ahh ! que c'est bon d'etre libre ^^
lol
|
Répondre
|
ça a l'air de bien marcher...
|
Répondre
|
roooo et les liens marche sur ce site ?!?
elle est pas belle la vie ???
elle est pas belle la vie ???
|
Répondre
|
j'ai hate que la p II kc du sein triple negatif associé à une chimiothérapie par gemcitabine ou carboplatine commence.
le recrutement est presque terminé ...
http://www.e-cancer.fr/recherche/recherche-clinique/registre-des-essais-cliniques/registre-des-essais-cliniques?task=detailEtude&idFiche=1478
AB 10002 : Essai de phase 1-2 randomisé évaluant l’efficacité et la tolérance du traitement par masitinib associé à une chimiothérapie par gemcitabine ou carboplatine, chez des patientes ayant un cancer du sein triple négatif métastasé ou localement avancé.
le recrutement est presque terminé ...
http://www.e-cancer.fr/recherche/recherche-clinique/registre-des-essais-cliniques/registre-des-essais-cliniques?task=detailEtude&idFiche=1478
AB 10002 : Essai de phase 1-2 randomisé évaluant l’efficacité et la tolérance du traitement par masitinib associé à une chimiothérapie par gemcitabine ou carboplatine, chez des patientes ayant un cancer du sein triple négatif métastasé ou localement avancé.
|
Répondre
|
Recruitment status Main ID Public Title Date of Registration
Not recruiting NCT02009423
Masitinib vs Placebo - Phase III Study to Compare the Efficacy and Safety of Masitinib to Placebo in Patients With Localized, Primary GIST After Complete Surgery and With High Risk of Recurrence 28/11/2013
Authorised EUCTR2012-005586-13-ES
A prospective, multicentre, randomised, double-blind, placebo-controlled, phase 2a study to compare the efficacy and the safety of 24-week treatment with masitinib versus placebo in patients with severe Chronic Obstructive Pulmonary Disease (COPD) 24/06/2013
Recruiting NCT01872598
A Phase 3 Study to Evaluate the Safety and Efficacy of Masitinib in Patients With Mild to Moderate Alzheimer's Disease 05/06/2013
Authorised EUCTR2010-022744-21-ES
A study to compare the saftey and efficacy of masitinib to placebo in the treatment of mood disorders in patients with antidepressant-resistant major depression or patients with dysthymic disorder 06/03/2013
Authorised EUCTR2010-024423-24-ES
Evaluation of masitinib in Amyotrophic Lateral Sclerosis (ALS) 29/11/2012
Authorised EUCTR2010-020603-79-ES
Evaluation of masitinib in acute ischemic stroke 22/10/2012
Recruiting NCT01694277
A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Comparison to Sunitinib in Patients With Gastrointestinal Stromal Tumour After Progression With Imatinib 22/08/2012
Not recruiting NCT01506336
A Phase 2 Study to Evaluate Efficacy and Safety of Masitinib in Comparison to Sunitinib in Patients With Gastro-Intestinal Stromal Tumour Resistant to Imatinib 03/01/2012
Recruiting CTRI/2011/11/002122
A clinical study of Masitinib at 6 mg/kg/day versus placebo in the treatment of patients with Severe Persistent Asthma treated with oral corticosteroids. 11-11-2011
Recruiting NCT01470131
A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Patients With Relapse or Refractory Multiple Myeloma 25/10/2011
Recruiting NCT01449162
A Phase 3 Study to Compare Efficacy and Safety of Masitinib to Placebo in Treatment of Patients With Severe Persistent Asthma Treated With Oral Corticosteroids 06/10/2011
Not recruiting NCT01450488
Masitinib in Patients With Primary Progressive Multiple Sclerosis (PPMS) or Relapse-free Secondary Progressive Multiple Sclerosis (SPMS) 06/10/2011
Recruiting NCT01433497
A Phase 2b/3 Study to Compare Efficacy and Safety of Masitinib to Placebo in the Treatment of Patients With Primary Progressive or Relapse-free Secondary Progressive Multiple Sclerosis 12/09/2011
Recruiting NCT01410695
A Phase 2b/3 Study to Evaluate Efficacy and Safety of Masitinib in Comparison to Methotrexate in Patients With Active Rheumatoid Arthritis With Inadequate Response to Methotrexate or to Any Disease-Modifying Antirheumatic Drug 04/08/2011
Authorised EUCTR2010-020992-21-CZ
Comparison of efficacy of masitinib versus methotrexate in the treatment of rheumatoid arthritis 18/07/2011
Authorised EUCTR2010-021219-17-ES
Evaluación de masitinib en esclerosis múltiple 01/07/2011
Authorised EUCTR2011-001790-41-FR
A prospective, multicenter, randomised, open-label, active-controlled, two-parallel groups, phase 3 study to compare the efficacy and safety of masitinib to sunitinib in patients with gastrointestinal stromal tumor resistant to imatinib 16/06/2011
Not recruiting NCT01266369
Masitinib in Patients With Mastocytosis With Handicap and Bearing the D816V Mutation 23/12/2010
Authorised EUCTR2010-022620-77-FR
A prospective, multicentre, open-label, randomised, uncontrolled, phase 1/2 study to evaluate efficacy and safety of masitinib in combination with etoposide, or masitinib in combination with irinotecan in patients with advanced hepatocellular carcinoma and who relapsed after a first line therapy with sorafenib. 01/10/2010
Not Recruiting EUCTR2010-021495-29-FR
A prospective, multicentre, randomised, double-blind, placebo-controlled, phase 2a study to compare the efficacy and the safety of 24-week treatment with masitinib at 6 mg/kg/day versus placebo in patients with severe Chronic Obstructive Pulmonary Disease (COPD) 06/09/2010
Authorised EUCTR2009-017918-69-DE
A study to compare masitinib with dacarbazine in the treatment of patient with advanced melanoma carrying a mutation in a gene called c-kit 04/08/2010
Not Recruiting EUCTR2010-020803-63-FR
A prospective, multicenter, randomised, double-blind, placebo-controlled, 2-parallel groups, Phase 3 study to compare the efficacy and the safety of masitinib at 6 mg/kg/day versus placebo in the treatment of patients with Severe Persistent Asthma treated with oral corticosteroids 20/07/2010
Not Recruiting EUCTR2010-021218-50-FR
A multicenter, double-blind, placebo-controlled, randomised, parallel-group phase 3 study to evaluate the safety and efficacy of masitinib in patients with mild to moderate Alzheimer’s disease 15/07/2010
Authorised EUCTR2009-017930-35-FR
A prospective, multicenter, randomized, double-blind, placebo-controlled, 2-parallel group, phase 3 study to compare efficacy and safety of masitinib 9 mg/kg/day in combination with bortezomib and dexamethazone to placebo in combination with bortezomib and dexamethazone in the treatment of patients with relapsing multiple myeloma who received one previous therapy 12/03/2010
Authorised EUCTR2010-018982-43-FR
A prospective, multicenter, open-label, uncontrolled, two-parallel group, phase 1/2 study to evaluate safety and efficacy of masitinib at 9 mg/kg/day in monotherapy and in combination with dacarbazine in the treatment of patients with non-resectable or metastatic stage 3 or stage 4 melanoma not carrying a mutation in the juxta membrane domain of c-kit 22/02/2010
Not recruiting NCT01045577
A Double-blind, Placebo-controlled, Randomized, Parallel-group Study to Evaluate the Activity of Oral AB1010 in Adults Patients With Moderate to Severe Chronic Plaque Psoriasis 08/01/2010
Not recruiting NCT00998751
A Phase 2 Study to Evaluate Efficacy and Safety of Masitinib in Non Pre-treated, Inoperable Patients With Locally Advanced/Metastatic Gastro-intestinal Stromal Tumour (GIST) 19/10/2009
Not recruiting NCT00976118
Activity of Masitinib (AB1010) in Mild to Moderate Alzheimer's Disease 11/09/2009
Not recruiting NCT00913432
A Phase 2 Study to Evaluate Efficacy and Safety of Masitinib in Combination With Methotrexate, in Treatment of Patients With Active Rheumatoid Arthritis 03/06/2009
Not recruiting NCT00866138
A Phase 2 Study to Evaluate Efficacy and Safety of Masitinib in Patients With Relapse or Refractory Multiple Myeloma With t(4/14) Translocation Expressing or Not FGFR3 19/03/2009
Not Recruiting EUCTR2008-000974-18-CZ
A prospective, multicenter, randomized, double-blind, placebo-controlled, 2-parallel group, Phase III study to compare efficacy and safety of masitinib at 9 mg/kg/day in combination with gemcitabine, to placebo in combination with gemcitabine, in treatment of patients with advanced/metastatic pancreatic cancer 19/02/2009
Not recruiting NCT00831974
Efficacy of AB1010 in Patients With Systemic Indolent Mastocytosis 28/01/2009
Not recruiting NCT00831922
Efficacy of Oral AB1010 in Adult Patients With Active Rheumatoid Arthritis 28/01/2009
Recruiting NCT00814073
A Phase 3 Study to Compare Efficacy and Safety of Masitinib to Placebo in the Treatment of Patients With Smouldering Systemic, Indolent Systemic or Cutaneous Mastocytosis With Handicap 22/12/2008
Not recruiting NCT00789633
A Phase 3 Study to Compare Efficacy and Safety of Masitinib in Combination With Gemcitabine, to Placebo in Combination With Gemcitabine, in Treatment of Patients With Advanced/Metastatic Pancreatic Cancer 12/11/2008
Authorised EUCTR2008-000973-40-FR
A prospective, multicenter, randomized, open-label, active-controlled, 2-parallel group, phase III study to compare efficacy and safety of masitinib at 7.5 mg/kg/day to imatinib at 400 or 600 mg in treatment of patients with gastro-intestinal stromal tumour in first line medical treatment 16/07/2008
Authorised EUCTR2008-000972-25-FR
A 24-week with possible extension, prospective, multicentre, randomized, double blind, placebo-controlled, 2-parallel group with a randomization 1:1, Phase III study to compare efficacy and safety of masitinib at 6 mg/kg/day to placebo in treatment of patients with Smouldering Systemic, Indolent Systemic or Cutaneous Mastocytosis with handicap 22/05/2008
Not recruiting NCT02009423
Masitinib vs Placebo - Phase III Study to Compare the Efficacy and Safety of Masitinib to Placebo in Patients With Localized, Primary GIST After Complete Surgery and With High Risk of Recurrence 28/11/2013
Authorised EUCTR2012-005586-13-ES
A prospective, multicentre, randomised, double-blind, placebo-controlled, phase 2a study to compare the efficacy and the safety of 24-week treatment with masitinib versus placebo in patients with severe Chronic Obstructive Pulmonary Disease (COPD) 24/06/2013
Recruiting NCT01872598
A Phase 3 Study to Evaluate the Safety and Efficacy of Masitinib in Patients With Mild to Moderate Alzheimer's Disease 05/06/2013
Authorised EUCTR2010-022744-21-ES
A study to compare the saftey and efficacy of masitinib to placebo in the treatment of mood disorders in patients with antidepressant-resistant major depression or patients with dysthymic disorder 06/03/2013
Authorised EUCTR2010-024423-24-ES
Evaluation of masitinib in Amyotrophic Lateral Sclerosis (ALS) 29/11/2012
Authorised EUCTR2010-020603-79-ES
Evaluation of masitinib in acute ischemic stroke 22/10/2012
Recruiting NCT01694277
A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Comparison to Sunitinib in Patients With Gastrointestinal Stromal Tumour After Progression With Imatinib 22/08/2012
Not recruiting NCT01506336
A Phase 2 Study to Evaluate Efficacy and Safety of Masitinib in Comparison to Sunitinib in Patients With Gastro-Intestinal Stromal Tumour Resistant to Imatinib 03/01/2012
Recruiting CTRI/2011/11/002122
A clinical study of Masitinib at 6 mg/kg/day versus placebo in the treatment of patients with Severe Persistent Asthma treated with oral corticosteroids. 11-11-2011
Recruiting NCT01470131
A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Patients With Relapse or Refractory Multiple Myeloma 25/10/2011
Recruiting NCT01449162
A Phase 3 Study to Compare Efficacy and Safety of Masitinib to Placebo in Treatment of Patients With Severe Persistent Asthma Treated With Oral Corticosteroids 06/10/2011
Not recruiting NCT01450488
Masitinib in Patients With Primary Progressive Multiple Sclerosis (PPMS) or Relapse-free Secondary Progressive Multiple Sclerosis (SPMS) 06/10/2011
Recruiting NCT01433497
A Phase 2b/3 Study to Compare Efficacy and Safety of Masitinib to Placebo in the Treatment of Patients With Primary Progressive or Relapse-free Secondary Progressive Multiple Sclerosis 12/09/2011
Recruiting NCT01410695
A Phase 2b/3 Study to Evaluate Efficacy and Safety of Masitinib in Comparison to Methotrexate in Patients With Active Rheumatoid Arthritis With Inadequate Response to Methotrexate or to Any Disease-Modifying Antirheumatic Drug 04/08/2011
Authorised EUCTR2010-020992-21-CZ
Comparison of efficacy of masitinib versus methotrexate in the treatment of rheumatoid arthritis 18/07/2011
Authorised EUCTR2010-021219-17-ES
Evaluación de masitinib en esclerosis múltiple 01/07/2011
Authorised EUCTR2011-001790-41-FR
A prospective, multicenter, randomised, open-label, active-controlled, two-parallel groups, phase 3 study to compare the efficacy and safety of masitinib to sunitinib in patients with gastrointestinal stromal tumor resistant to imatinib 16/06/2011
Not recruiting NCT01266369
Masitinib in Patients With Mastocytosis With Handicap and Bearing the D816V Mutation 23/12/2010
Authorised EUCTR2010-022620-77-FR
A prospective, multicentre, open-label, randomised, uncontrolled, phase 1/2 study to evaluate efficacy and safety of masitinib in combination with etoposide, or masitinib in combination with irinotecan in patients with advanced hepatocellular carcinoma and who relapsed after a first line therapy with sorafenib. 01/10/2010
Not Recruiting EUCTR2010-021495-29-FR
A prospective, multicentre, randomised, double-blind, placebo-controlled, phase 2a study to compare the efficacy and the safety of 24-week treatment with masitinib at 6 mg/kg/day versus placebo in patients with severe Chronic Obstructive Pulmonary Disease (COPD) 06/09/2010
Authorised EUCTR2009-017918-69-DE
A study to compare masitinib with dacarbazine in the treatment of patient with advanced melanoma carrying a mutation in a gene called c-kit 04/08/2010
Not Recruiting EUCTR2010-020803-63-FR
A prospective, multicenter, randomised, double-blind, placebo-controlled, 2-parallel groups, Phase 3 study to compare the efficacy and the safety of masitinib at 6 mg/kg/day versus placebo in the treatment of patients with Severe Persistent Asthma treated with oral corticosteroids 20/07/2010
Not Recruiting EUCTR2010-021218-50-FR
A multicenter, double-blind, placebo-controlled, randomised, parallel-group phase 3 study to evaluate the safety and efficacy of masitinib in patients with mild to moderate Alzheimer’s disease 15/07/2010
Authorised EUCTR2009-017930-35-FR
A prospective, multicenter, randomized, double-blind, placebo-controlled, 2-parallel group, phase 3 study to compare efficacy and safety of masitinib 9 mg/kg/day in combination with bortezomib and dexamethazone to placebo in combination with bortezomib and dexamethazone in the treatment of patients with relapsing multiple myeloma who received one previous therapy 12/03/2010
Authorised EUCTR2010-018982-43-FR
A prospective, multicenter, open-label, uncontrolled, two-parallel group, phase 1/2 study to evaluate safety and efficacy of masitinib at 9 mg/kg/day in monotherapy and in combination with dacarbazine in the treatment of patients with non-resectable or metastatic stage 3 or stage 4 melanoma not carrying a mutation in the juxta membrane domain of c-kit 22/02/2010
Not recruiting NCT01045577
A Double-blind, Placebo-controlled, Randomized, Parallel-group Study to Evaluate the Activity of Oral AB1010 in Adults Patients With Moderate to Severe Chronic Plaque Psoriasis 08/01/2010
Not recruiting NCT00998751
A Phase 2 Study to Evaluate Efficacy and Safety of Masitinib in Non Pre-treated, Inoperable Patients With Locally Advanced/Metastatic Gastro-intestinal Stromal Tumour (GIST) 19/10/2009
Not recruiting NCT00976118
Activity of Masitinib (AB1010) in Mild to Moderate Alzheimer's Disease 11/09/2009
Not recruiting NCT00913432
A Phase 2 Study to Evaluate Efficacy and Safety of Masitinib in Combination With Methotrexate, in Treatment of Patients With Active Rheumatoid Arthritis 03/06/2009
Not recruiting NCT00866138
A Phase 2 Study to Evaluate Efficacy and Safety of Masitinib in Patients With Relapse or Refractory Multiple Myeloma With t(4/14) Translocation Expressing or Not FGFR3 19/03/2009
Not Recruiting EUCTR2008-000974-18-CZ
A prospective, multicenter, randomized, double-blind, placebo-controlled, 2-parallel group, Phase III study to compare efficacy and safety of masitinib at 9 mg/kg/day in combination with gemcitabine, to placebo in combination with gemcitabine, in treatment of patients with advanced/metastatic pancreatic cancer 19/02/2009
Not recruiting NCT00831974
Efficacy of AB1010 in Patients With Systemic Indolent Mastocytosis 28/01/2009
Not recruiting NCT00831922
Efficacy of Oral AB1010 in Adult Patients With Active Rheumatoid Arthritis 28/01/2009
Recruiting NCT00814073
A Phase 3 Study to Compare Efficacy and Safety of Masitinib to Placebo in the Treatment of Patients With Smouldering Systemic, Indolent Systemic or Cutaneous Mastocytosis With Handicap 22/12/2008
Not recruiting NCT00789633
A Phase 3 Study to Compare Efficacy and Safety of Masitinib in Combination With Gemcitabine, to Placebo in Combination With Gemcitabine, in Treatment of Patients With Advanced/Metastatic Pancreatic Cancer 12/11/2008
Authorised EUCTR2008-000973-40-FR
A prospective, multicenter, randomized, open-label, active-controlled, 2-parallel group, phase III study to compare efficacy and safety of masitinib at 7.5 mg/kg/day to imatinib at 400 or 600 mg in treatment of patients with gastro-intestinal stromal tumour in first line medical treatment 16/07/2008
Authorised EUCTR2008-000972-25-FR
A 24-week with possible extension, prospective, multicentre, randomized, double blind, placebo-controlled, 2-parallel group with a randomization 1:1, Phase III study to compare efficacy and safety of masitinib at 6 mg/kg/day to placebo in treatment of patients with Smouldering Systemic, Indolent Systemic or Cutaneous Mastocytosis with handicap 22/05/2008
|
Répondre
|
Forum de discussion Ab Science
201401061821 383881
Suivez les marchés avec des outils de pros !